To the full analysis
10x Genomics stock: growth
TXG10x Genomics reported $642.82M in revenue for fiscal 2025, up 5.2% on the prior year, up 16.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
31.7%
per year from 2017 to 2025, per share −2.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2017 | |
|---|---|---|
| Revenue | 16.6% | 31.7% |
| Revenue per share | 11.8% | −2.2% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2017 | $71.09M | −$18.76M | −$14.46M |
| 2018 | $146.31M | −$112.49M | −$83.12M |
| 2019 | $245.89M | −$31.25M | −$8.14M |
| 2020 | $298.85M | −$542.73M | −$256.29M |
| 2021 | $490.49M | −$58.22M | −$122.65M |
| 2022 | $516.41M | −$166M | −$165.27M |
| 2023 | $618.73M | −$255.1M | −$64.72M |
| 2024 | $610.79M | −$182.63M | −$5.73M |
| 2025 | $642.82M | −$43.54M | $130.12M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 29 May 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.